Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target on Travere Therapeutics (NASDAQ:TVTX) to $32.00, up from the previous $27.00, while retaining a Sector Outperform rating for the ...
El Mundo on MSN2h
US approves a new painkiller with less risk of addiction than opioids and equally potentThe suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out ...
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for ...
The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
They are important niches to the scientists who can now solve previously unsolvable problems, but they may not constitute ...
The FDA has made some modest efforts, but it needs an internal organization that understands and would be an aggressive ...
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...
"AI is going to help kick in some of that load that the scientists and researchers do at the front end to quickly get a diagnosis," said Deema Tarazi.
Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback